Skip to main content

Table 5 Most frequently reported adverse events (in ≥ 5% of patients in any treatment group). Patients administered C.E.R.A. QW or Q3W.

From: Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

 

C.E.R.A. dose group (μg/kg QW)

C.E.R.A. dose group (μg/kg Q3W)

Adverse event, n (%)

0.7 (n = 36)

1.4 (n = 37)

2.1 (n = 35)

2.1 (n = 34)

4.2 (n = 37)

6.3 (n = 34)

Nausea

12 (33)

6 (16)

11 (31)

11 (32)

7 (19)

4 (12)

Fatigue

11 (31)

8 (22)

7 (20)

6 (18)

10 (27)

7 (21)

Anorexia

7 (19)

7 (19)

7 (20)

6 (18)

7 (19)

6 (18)

Vomiting

8 (22)

7 (19)

9 (26)

6 (18)

2 (5)

6 (18)

Neutropenia

9 (25)

3 (8)

6 (17)

8 (24)

7 (19)

4 (12)

Asthenia

5 (14)

5 (14)

5 (14)

6 (18)

5 (14)

4 (12)

Cough

8 (22)

3 (8)

3 (9)

5 (15)

4 (11)

4 (12)

Diarrhea

6 (17)

5 (14)

4 (11)

3 (9)

6 (16)

3 (9)

  1. C.E.R.A.: Continuous Erythropoietin Receptor Activator.
  2. QW: once weekly.
  3. Q3W: once every 3 weeks.